QuidelOrtho Reports $1.13B Net Loss, $700M Goodwill Impairment, Exits SAVANNA Platform Amid Restructuring

summarizeSummary

QuidelOrtho reported a $1.13 billion net loss for fiscal year 2025, including a $700.7 million goodwill impairment and charges related to the discontinuation of its SAVANNA platform and a joint business termination. The company is implementing a multi-year restructuring plan while successfully remediating prior material weaknesses in internal controls.

check_boxKey Events

• Significant Net Loss Reported

  The company reported a net loss of $1.13 billion for fiscal year 2025, following a $2.05 billion net loss in 2024, reflecting ongoing financial challenges.

• Substantial Goodwill Impairment

  QuidelOrtho recognized a non-cash goodwill impairment charge of $700.7 million in 2025, fully impairing goodwill for its EMEA, China, and Latin America reporting units. This follows a $1.8 billion impairment in 2024.

• Strategic Product & Business Exits

  The company is discontinuing its SAVANNA platform, incurring $149.7 million in asset impairment/write-off charges, and is winding down its U.S. donor screening portfolio, contributing to revenue decline.

• Major Restructuring Initiative

  An 'Optimization Plan' was launched in Q2 2025, projecting $100 million in pre-tax charges through 2027 for cost reduction and operational efficiency, with expected net savings of $50 million.

auto_awesomeAnalysis

QuidelOrtho's annual report reveals a challenging fiscal year 2025, marked by a substantial net loss of $1.13 billion and a significant non-cash goodwill impairment charge of $700.7 million. This impairment fully impacted the EMEA, China, and Latin America reporting units, following a $1.8 billion impairment in 2024, indicating a continued re-evaluation of asset values. The company is undergoing major strategic shifts, including the discontinuation of its SAVANNA platform, which resulted in $149.7 million in asset impairment/write-off charges, and the wind-down of its U.S. donor screening portfolio. Additionally, QuidelOrtho initiated an 'Optimization Plan' with expected pre-tax charges of $100 million through 2027, aiming for $50 million in net cost savings. A $65 million charge was also recorded for the termination of a joint business arrangement with Grifols. While total revenues saw a modest 2% decrease, driven by declining COVID-19 product sales, the company did report growth in its Labs segment. A positive development is the full remediation of previously reported material weaknesses in internal control over financial reporting, enhancing financial reliability. However, the magnitude of the financial losses, impairments, and strategic exits points to significant operational and financial challenges.